changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
21 June 2013
Further to the announcement made on 23 May 2013, BTG plc (BTG or the Company) has today published and sent to all holders of Ordinary Shares in the capital of BTG (BTG Shareholders) a circular (the Circular) in relation to the proposed acquisition by a subsidiary of BTG of the Targeted Therapies division of Nordion Inc. (the Acquisition). The Circular has been prepared in accordance with the Listing Rules of the Financial Conduct Authority.
The Acquisition is subject to the approval of BTG Shareholders, and, accordingly, the Circular contains a notice convening a general meeting of the Company which is to be held at the offices of Allen & Overy LLP, One Bishops Square, London E1 6AD at 9.30a.m. on 11 July 2013.
Copies of the Circular and the notice of general meeting are available for viewing on the Company's website at http://www.btgplc.com/investors/circular-to-shareholders-and-notice-of-general-meeting and have been submitted to the National Storage Mechanism, and will shortly be available for inspection on the National Storage Mechanism's website www.hemscott.com/nsm.do.
BTG plc: +44 (0) 20 7575 0000
Louise Makin - Chief Executive Officer
Rolf Soderstrom - Chief Financial Officer
Andy Burrows, Director of Investor Relations, +44 (0) 20 7575 1741
J.P. Morgan Cazenove: +44 (0)20 7742 4000
FTI Consulting: +44 (0) 20 7831 3113
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com